ASNA-1 oxidation induced by cisplatin exposure enhances its cytotoxicity by selectively perturbing tail anchored protein targeting
Preprint
- 28 October 2019
- preprint
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 821728
Abstract
Cisplatin is a frontline cancer treatment, but intrinsic or acquired resistance is common. We previously showed that ASNA-1/TRC40 inactivation increases cisplatin sensitivity in mammalian cells and aCaenorhabditis elegans asna-1knockdown model. ASNA-1 has conserved tail-anchored protein (TAP) targeting and insulin secretion functions. Here we examined the mechanism of ASNA-1 action. We show that ASNA-1 exists in two physiologically-responsive redox states with separable TAP-targeting and insulin secretion functions. Cisplatin-generated ROS targeted ASNA-1 oxidation, resulting in a selective targeting defect of an ASNA-1-dependent TAP. Increased ASNA-1 oxidation sensitized worms to cisplatin cytotoxicity. Mutants with a redox balance favoring oxidized ASNA-1 were cisplatin sensitive as null mutants by diverting ASNA-1 away from its TAP-targeting role and instead perturbing endoplasmic reticulum (ER) function. Mutations in the ASNA-1 receptor required for TAP insertion induced equivalent cisplatin sensitivity. We reveal a previously undescribed cellular dysfunction induced by cisplatin, identify a cisplatin target, and show that drug exposure causes TAP targeting-induced ER dysfunction. Therapeutic oxidation of ASNA-1 could be a clinically useful means to increase cisplatin sensitivity, reduce cytotoxic drug doses, and counteract cisplatin resistance.AUTHOR SUMMARY: Cisplatin is a very effective anti-cancer drug and is widely used as a frontline treatment. However, tumor resistance limits its use. Tumor re-sensitization would improve cancer treatment. ASNA-1/TRC40 knockdown inCaenorhabditis elegansand mammals results in cisplatin hypersensitivity, but the underlying mechanistic details are largely unknown. We show that inC. elegansASNA-1 mutants, increased cisplatin killing is coupled with delocalization of a tail-anchored protein, SEC-61β, a membrane protein that should reach the ER and is instead mistargeted. Like its homologs, the reduced form of worm ASNA-1 is needed for targeting activity. Targeting is blocked upon ASNA-1 oxidation after cisplatin treatment, likely via reactive oxygen species (ROS) generated by cisplatin treatment. Nevertheless, the oxidized form of the protein can execute other functions like insulin secretion. We show also that mutants with high oxidized ASNA-1 levels are cisplatin sensitive. Additionally, cisplatin induced mistargeting strictly acts through ASNA-1 inactivation. Thus, we define a pathway from cisplatin exposure that targets protein (ASNA-1) inactivation, consequently leading to mis-targeting of proteins that need ASNA-1 for their maturation. This multi-step process provides vital information about likely proteins that can be targeted by drugs to enhance cisplatin mediated killing and improve chemotherapy.SUMMARY STATEMENT: Sensitizing tumors to cisplatin would be of considerable therapeutic benefit. Here we show a novel mechanism of cisplatin sensitization via oxidation of ASNA-1 in aCaenorhabditis elegansmodel.Keywords
This publication has 61 references indexed in Scilit:
- The WRB Subunit of the Get3 Receptor is Required for the Correct Integration of its Partner CAML into the ERScientific Reports, 2019
- A Chaperone Lid Ensures Efficient and Privileged Client Transfer during Tail-Anchored Protein TargetingCell Reports, 2019
- Substrate relay in an Hsp70‐cochaperone cascade safeguards tail‐anchored membrane protein targetingThe EMBO Journal, 2018
- Targeting and translocation of proteins to the endoplasmic reticulum at a glanceJournal of Cell Science, 2017
- Multiple pathways facilitate the biogenesis of mammalian tail-anchored proteinsJournal of Cell Science, 2017
- The SND proteins constitute an alternative targeting route to the endoplasmic reticulumNature, 2016
- A Directed RNAi Screen Based on Larval Growth Arrest Reveals New Modifiers of C. elegans Insulin SignalingPLOS ONE, 2012
- Exploring real-time in vivo redox biology of developing and aging Caenorhabditis elegansFree Radical Biology and Medicine, 2012
- The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatinCritical Reviews in Toxicology, 2010
- Post-translational integration of tail-anchored proteins is facilitated by defined molecular chaperonesJournal of Cell Science, 2007